Under the EU Health Technology Assessment Regulation, joint scientific consultations (JSCs) allow developers of medicines and medical devices to discuss study design with national health technology assessment bodies so that future evidence packages better match joint clinical assessment requirements. This is the third submission period since the Regulation started to apply on 12 January 2025, following two rounds last year that delivered seven JSCs, of which four are already finalised.
The new submission window runs from 7 January to 4 February 2026 and is open to developers of both medicines and medical devices, with no fee for participation. Developers can also request that JSCs run in parallel with scientific advice from the European Medicines Agency (EMA), creating a single meeting that brings together EMA assessors, national HTA experts and the company’s team.
Consultation slots under this call correspond to briefing documents due on 7 April, 4 May and 8 June 2026. Requests must be submitted through the HTA IT Platform by 4 February 2026, and the Commission stresses that registration can take several days, making early action essential for companies that want to secure a slot.
Source: European Commission – Directorate‑General for Health and Food Safety
Link: Health Technology Assessment: New Opportunity to Apply for Joint Scientific Consultations
Date: 7 January 2026
